Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0487-0111 in Participants With Various Degrees of Renal Impairment and Normal Renal Function
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Amycretin (Primary)
- Indications Kidney disorders
- Focus Pharmacodynamics
- Sponsors Novo Nordisk
- 09 Jan 2025 Planned End Date changed from 27 Feb 2025 to 25 Feb 2025.
- 09 Jan 2025 Planned primary completion date changed from 27 Feb 2025 to 25 Feb 2025.
- 09 Jan 2025 Status changed from not yet recruiting to recruiting.